Quality & Patient Safety

Anticoagulant National Patient Safety Goal updated

Patient Safety Monitor, March 1, 2019

This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Patient Safety Monitor.

The Joint Commission (TJC) announced revisions to its anticoagulant therapy National Patient Safety Goal (NPSG) December 7. NPSG 03.05.01 has eight new or revised elements of performance (EP).

All the changes are listed in R3 Report 19 and will take effect July 1, 2019. The update applies to all TJC-accredited hospitals, critical access hospitals, nursing care centers, and medical centers accredited under the ambulatory healthcare program.

The report explains that while this NPSG has made a positive impact on patient safety over the years, there’s been a rise in adverse events because of an increase in the use of direct oral anticoagulants (DOAC).

EP 1: Protocols for starting and continuing anticoagulant treatment must be evidence-based

Anticoagulant medicines are considered high-risk for a number of reasons. The dosing is complex, patients often don’t follow instructions, and providers can fall through on monitoring. 

Facilities need to ensure their protocols are updated to cover all types of anticoagulants, including DOACs.

EP 2: Anticoagulation reversal and bleeding management protocols must be evidence-based

This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Patient Safety Monitor.

Most Popular